Biological and glucocorticoids treatment impair the medium-term immunogenicity to SARS-CoV-2 mRNA vaccines in autoimmune inflammatory rheumatic diseases.

Overall, the use of GCs was associated with a 58% decrease in baseline antiS-AB levels and a 36% decrease after the administration of the third SARS-CoV-2 vaccine dose, although these differences did not reach statistical significance ( p values 0.0577 and 0.2931, respectively; Table 4 ).

also in 111,027 other papers